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Summary
Background Sickle cell disease contributes substantially to mortality in children younger than 5 years in sub-Saharan 
Africa. In Uganda, 20 000 babies per year are thought to be born with sickle cell disease, but accurate data are not 
available. We did the cross-sectional Uganda Sickle Surveillance Study to assess the burden of disease.
Methods The primary objective of the study was to calculate prevalence of sickle cell trait and disease. We obtained 
punch samples from dried blood spots routinely collected from HIV-exposed infants in ten regions and 112 districts 
across Uganda for the national Early Infant Diagnosis programme. Haemoglobin electrophoresis by isoelectric 
focusing was done on all samples to identify those from babies with sickle trait or disease.
Findings Between February, 2014, and March, 2015, 99 243 dried blood spots were analysed and results were available 
for 97 631. The overall number of children with sickle cell trait was 12 979 (13·3%) and with disease was 716 (0·7%). 
Sickle cell numbers ranged from 631 (4·6%) for trait and 23 (0·2%) for disease of 13 649 in the South Western region 
to 1306 (19·8%) for trait and 96 (1·5%) for disease of 6581 in the East Central region. Sickle cell trait was seen in all 
districts. The lowest prevalence was less than 3·0% in two districts. Eight districts had prevalence greater than 20·0%, 
with the highest being 23·9%. Sickle cell disease was less common in children older than 12 months or who were 
HIV positive, which is consistent with comorbidity and early mortality. 
Interpretation Prevalence of sickle cell trait and disease were high in Uganda, with notable variation between regions 
and districts. The data will help to inform national strategies for sickle cell disease, including neonatal screening.
Funding Cincinnati Children’s Research Foundation.
Copyright © Ndeezi et al. Open Access article distributed under the terms of CC BY-NC-ND.
Introduction
Sickle cell disease refers to a group of inherited 
haemoglobin disorders characterised by a predominance 
of abnormal sickle haemoglobin in erythrocytes.1 Sickle 
cell anaemia, which results from homozygous 
inheritance of sickle haemoglobin from both parents, is 
the most common and severe form of sickle cell disease. 
On deoxygenation, sickle haemoglobin undergoes a 
conformational change that promotes intracellular 
polymerisation, which leads to distortion of the normal 
biconcave erythrocyte disc into the distinctive and 
pathological crescent shape. The resulting haemolytic 
anaemia manifests as recurrent vaso-occlusion and 
organ damage that together cause substantial morbidity 
and early mortality.1
Worldwide, sickle haemoglobinopathies lead to a sub-
stantial burden of disease that is not adequately 
addressed.2–4 Accurate data are lacking, but the worldwide 
estimate for neonates born with sickle cell disease each 
year is 400 000, including 300 000 with sickle cell anaemia.5 
The greatest burden is seen in sub-Saharan Africa, where 
more than 75% of all sickle cell disease occurs, with this 
proportion projected to increase by 2050.6 In Africa, sickle 
cell disease contributes substantially to mortality in 
children younger than 5 years and, therefore, limits 
progress towards achieving UN Sustainable Development 
Goal 3, Good Health and Well-Being, which includes the 
reduction of childhood mortality.7,8
In 2006, WHO issued an important report on sickle 
cell disease in the African region, which described the 
overall prevalence and provided guidelines on care and 
management strategies.9 WHO also publicised the need 
to improve sickle cell awareness, disease prevention, and 
early detection.10 Countries in sub-Saharan Africa have 
been challenged by WHO to formulate national 
strategies for sickle cell disease that address speciﬁ c 
aims, targets, and objectives. Despite this charge, 
ministries of health are hindered from creating 
meaningful interventions by many obstacles, including 
lack of accurate data about the burden and distribution 
of disease within their countries.11
Uganda was among the ﬁ rst countries in Africa with a 
documented large burden of sickle cell disease. In 1949, 
substantial diﬀ erences in the prevalence of sickle cell 
trait were reported between diﬀ erent tribes, ranging 
from less than 5% for Hamites in the southwest to more 
than 20% for the northern Nilotices (Lango and Acholi). 
Some Bantu tribes had even higher rates, including 45% 
among Bamba living in the western region.12 A later 
study, however, has suggested lower values.13 Of note, 
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though, both studies were based on small samples and 
were not representative of the whole country.
The Ugandan Ministry of Health recognised the need for 
accurate, up-to-date data on the burden of sickle cell trait 
and disease to inform its eﬀ orts to pilot neonatal screening, 
begin early education and preventive measures, and 
eventually create a national strategy. We hypothesised that 
there is a large burden of sickle cell trait and disease across 
Uganda, but with substantial geographical variability. A 
partnership was established between Cincinnati Children’s 
Hospital, Cincinnati, OH, USA, and Makerere University, 
Kampala, Uganda, to enable the Ministry of Health to do a 
large cross-sectional research study, the Uganda Sickle 
Surveillance Study (US3), to generate such data.
Methods
Programme development
The Ugandan Ministry of Health has an active programme 
for prevention of mother-to-child transmission of HIV that 
identiﬁ es and treats infected mothers and their exposed 
infants. Infected mothers receive antiretroviral drug 
therapy during pregnancy and exposed babies receive 
6 weeks of treatment after birth, followed by testing with 
viral PCR for acquired HIV infection, typically before age 
6 months. Around 100 000 HIV-exposed infants are tested 
each year through the Early Infant Diagnosis programme, 
which includes a national sample transport system.14 Dried 
blood spots (DBS) are collected from exposed infants at 
health-care facilities across the country, carried by 
motorcycle to laboratory hubs at the subdistrict level, and 
shipped by courier to the Central Public Health Laboratories 
in the capital, Kampala.14 Sample testing is completed 
within 3 weeks of collection, after which DBS are stored at 
–20° C for about 1 year then discarded. The DBS collected 
between February, 2014, and March, 2015, were shared 
with the newly created sickle cell laboratory in the Central 
Public Health Laboratories within 1 week of HIV testing, to 
test for normal and abnormal haemoglobins.
The study protocol was approved with a waiver for 
informed consent by the School of Medicine Research 
Ethics Committee at Makerere University and the 
Uganda National Council for Science and Technology in 
Kampala. The study was also formally approved by the 
Cincinnati Children’s Hospital Medical Center 
Institutional Review Board.
Haemoglobin testing
The laboratory methods for haemoglobin testing were 
based on those previously described for a pilot neonatal 
haemoglobinopathy screening programme in Angola.15 
DBS were eluted and analysed by isoelectric focusing for 
the presence of normal and abnormal haemoglobins. 
Isoelectric focusing readily distinguishes between normal 
and sickle haemoglobin even in the presence of fetal 
haemoglobin. Staﬀ  at the Central Public Health 
Laboratories received on-site training by a technical team 
from Cincinnati Children’s Hospital on the study 
protocol, isoelectric focusing procedures, and inter-
pretation of results. Additional sessions were provided 
remotely for further training, troubleshooting, and overal 
technical laboratory support. 
The gel bands were independently compared with a 
standard control by two laboratory technicians and 
reviewed by the laboratory technologist to derive the ﬁ nal 
Research in context 
Evidence before this study
Decades have passed since the initial descriptions of sickle cell 
trait in diﬀ erent regions of Uganda, but accurate data on 
prevalence are unavailable. We searched PubMed for articles 
published in English up to May, 2015, with the search terms 
“sickle cell”, “screening“, “Uganda”, “Africa”, and “haemoglobin 
electrophoresis“. We identiﬁ ed four articles published before 
1960 that described ethnic origin and distribution of sickle cell 
trait and disease in Uganda. We found one paper from 2010 
that described the distribution of sickle cell trait in several 
regions of Uganda and seven reports since 2005 that provided 
pilot neonatal screening data in other sub-Saharan African 
locations, but could ﬁ nd no comprehensive surveillance data at 
the national level. 
Added value of this study
The primary study objective of the Uganda Sickle Surveillance 
Study was to generate critical data on the prevalence of sickle 
cell trait and disease. Comorbidities that might be associated 
with early mortality in people with sickle cell disease were also 
explored. This national-level surveillance study in sub-Saharan 
Africa documents a high burden in Uganda, with wide 
distribution of sickle cell trait and disease in every region and 
district. These national data will inform the Ministry of Health 
about next steps, including the launch of neonatal screening 
and development of a national sickle cell strategy. We also 
found that frequency of sickle cell disease declined in children 
older than 12 months or with HIV, which was consistent with 
comorbidity and early mortality.
Implications of all the available evidence
The Ugandan Ministry of Health needed accurate data on 
the prevalence and distribution of sickle cell trait and disease 
to help the country follow the WHO guidelines for clinical 
management. In view of our results, targeted neonatal 
screening for sickle cell disease is now warranted in the 
districts with the highest burden, along with eﬀ orts to 
improve education of health-care providers and awareness 
among the public and the government. Similar studies can be 
done in other sub-Saharan countries to help the development 
of national strategies for the management of sickle cell 
disease.
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classiﬁ cation of normal, sickle cell trait, sickle cell 
disease, or variant (table 1). To verify the accuracy of the 
laboratory process, for the ﬁ rst 3 months of the study all 
samples classiﬁ ed as sickle cell trait or sickle cell disease 
were retested in a second DBS punch. Accuracy was 
higher than 99%. After 3 months, only samples classiﬁ ed 
as sickle cell disease were retested. If the ﬁ rst result was 
indeterminate, a second DBS punch was tested in an 
attempt to obtain a valid result. If the second test was 
indeterminate, samples were excluded at that point. 
Results were recorded along with the age of the infant at 
the time of DBS collection, location by region and 
district, and HIV status, which are collected in the Early 
Infant Diagnosis programme. Quality control for 
accuracy of data was periodically assessed by researchers 
in Cincinnati and was consistently greater than 97%. 
Haemoglobin results were communicated to the 
collection sites with the existing HIV notiﬁ cation system.
Statistical analysis
The primary study objective was calculation of the 
prevalence of sickle cell trait and disease by district and 
region. Secondary objectives were to calculate the eﬀ ects 
of age and comorbidities on early mortality in children 
with sickle cell disease. Frequencies and percentages were 
calculated for ten regions and 112 districts. The relations 
between sickle cell disease, age, HIV status, and mortality 
were investigated by calculation of odds ratios and 
95% CIs with the χ² test for binary variables. Reductions 
in prevalence of sickle cell disease with increasing age or 
positive HIV status were assumed to reﬂ ect early mortality. 
Correlation between prevalence of sickle cell trait and 
malaria (children aged 0–59 months with positive 
microscopy16) by region was tested with linear regression.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication. 
Results
DBS from 99 243 infants and children were analysed. 
98 519 (99·3%) of samples were collected from children 
younger than 18 months (median age 2 months, 
IQR 2–9), with an equal distribution of boys and girls. 
Adult 
haemoglobin
Sickle 
haemoglobin
Fetal 
haemoglobin
Unknown 
haemoglobin
Normal Present None Variable None
Trait Present Present Variable None
Sickle None Present Variable None
Variant Present None Variable Present
Table 1: Haemoglobin classiﬁ cations for isoelectric focusing analysis 
Median 
(IQR) age 
(months)
Sex (boys/girls/unknown [%]) Normal 
(%)
Sickle 
cell trait 
(%)
Sickle cell 
disease 
(%)
Variant 
(%)
Central 1 
(n=14 756)
2 (2–8) 7127 (48·3%)/7430 (50·4%)/ 
199 (1·3%)
12 757
(86·5%)
1896
(12·8%)
69
(0·5%)
34
(0·2%)
Central 2 
(n=11 135)
2 (2–8) 5364 (48·2%)/5661 (50·8%)/ 
110 (1·0%)
9442
(84·8%)
1566
(14·1%)
94
(0·8%)
33
(0·3%)
East Central 
(n=6581)
3 (2–12) 3275 (49·8%)/3243 (49·3%)/ 
63 (1·0%)
5131
(78·0%)
1306
(19·8%)
96
(1·5%)
48
(0·7%)
Kampala 
(n=13 466)
2 (2–8) 6670 (49·5%)/6607 (49·1%)/ 
189 (1·4%)
11 499
(85·4%)
1835
(13·6%)
90
(0·7%)
42
(0·3%)
Mid Eastern 
(n=4865)
3 (2–11) 2342 (48·1%)/2455 (50·5%)/ 
68 (1·4%)
4014
(82·5%)
752
(15·5%)
60
(1·2%)
39
(0·8%)
Mid Northern 
(n=12 760)
3 (2–12) 6220 (48·7%)/6401 (50·2%)/ 
139 (1·1%)
10 028
(78·6%)
2445
(19·2%)
160
(1·3%)
127
(1·0%)
Mid Western 
(n=12 945)
2 (2–10) 6271 (48·4%)/6507 (50·3%)/ 
167 (1·3%)
11 418
(88·2%)
1431
(11·1%)
64
(0·5%)
32
(0·2%)
North East 
(n=4458)
2 (2–10) 2201 (49·4%)/2204 (49·4%)/ 
53 (1·2%)
3676
(82·5%)
702
(15.7%)
46
(1·0%)
34
(0·8%)
South Western 
(n=13 649)
3 (2–11) 6543 (47·9%)/6896 (50·5%)/ 
210 (1·5%)
12 979
(95·1%)
631
(4·6%)
23
(0·2%)
16
(0·1%)
West Nile 
(n=3016)
2 (2–12) 1566 (51·9%)/1406 (46·6%)/ 
44 (1·5%)
2534
(84·0%)
415
(13·8%)
14
(0·5%)
53
(1·8%)
All (n=97 631) 2 (2–9) 47 579 (48·7%)/48 810 
(50·0%)/1242 (1·3%)
83 478
(85·5%)
12 979
(13·3%)
716
(0·7%)
458
(0·5%)
Table 2: Haemoglobin results, by region 
>21·0–24·0%
>18·0–21·0%
>15·0–18·0%
>12·0–15·0%
>9·0–12·0%
>6·0–9·0%
>3·0–6·0%
≤3·0%
Prevalence
Figure 1: Prevalence of sickle cell trait in 112 districts in Uganda
Prevalence ranged from 2·5% to 23·9%.
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1612 (1·6%) samples did not yield a valid isoelectric 
focusing result and could not be classiﬁ ed and, therefore, 
97 631 were included in the analysis. The overall number 
of children with sickle cell trait was 12 979 (13·3%) and 
ranged from 631 (4·6%) of 13 649 in the South Western 
region to 1306 (19·8%) of 6581 in the East Central region. 
The overall number with sickle cell disease was 
716 (0·7%) and ranged from 23 (0·2%) of 13 649 in the 
South Western region to 96 (1·5%) of 6581 in the East 
Central region (table 2).
Sickle cell trait was found in all 112 districts (ﬁ gure 1, 
appendix). Those in the South Western region had the 
lowest prevalence, being less than 5% in nine and less 
than 3% in two. Eight districts had prevalence greater 
than 20%, with the highest being 23·9% in Alebtong.
The national prevalence of haemoglobin variants, 
speciﬁ cally those other than sickle haemoglobin, was 
0·5%, but ranged from 0·1% in the South Western 
region to 1·8% in the West Nile region (table 2). The 
highest frequency of DBS with variants by district was 
seen in Arua, with 26 (2·7%) in 973. 
Comparison of the data for prevalence of sickle cell 
trait and malaria in ten regions showed good overall 
visual concordance (ﬁ gure 2). The numerical data 
supported this ﬁ nding, showing strong correlation 
between sickle cell trait and malaria prevalence (r=0·69, 
p=0⋅026, appendix).
Prevalence of sickle cell disease fell with increasing age 
(table 3). The odds ratio for mortality was 0·79 (95% CI 
0·64–0·97, p=0⋅027) for the oldest age group compared 
with the youngest, which suggests early mortality in 
babies born with sickle cell disease. The odds ratio of 
having sickle cell disease for infants with positive versus 
negative HIV status was 0·60 (95% CI 0·40–0·91, 
p=0⋅022), which is consistent with early mortality due to 
HIV in babies with sickle cell disease, irrespective of age.
Discussion
We used haemoglobin testing of around 100 000 infants 
to provide quantitative data on the prevalence and 
distribution of sickle cell trait and disease across Uganda. 
The data showed an enormous burden, with sickle cell 
trait being present in all 112 districts assessed. Prevalence 
was highest in the Mid Northern and East Central regions. 
Overall, the prevalence of sickle cell trait was 13⋅3%, but 
it was more than 20% in eight districts. Among babies 
aged 6 months or younger, the overall prevalence of sickle 
cell trait was 13·2% and of disease was 0·8%, which 
suggests that at least 15 000 babies per year are born with 
sickle cell disease in Uganda. The prevalence of sickle cell 
disease approached or exceeded 1⋅0% in four regions, 
Figure 2: Prevalence of sickle cell trait and malaria in ten regions in Uganda
(A) Prevalence of sickle cell trait. (B) Prevalence of malaria, based on the Uganda Bureau of Statistics 2009 surveillance project.16
A B
19·8%
4·6%
62·5%
Prevalence Prevalence
4·9%
All Sickle cell 
trait (%)
Sickle cell 
disease (%)
Age (months)
0–6·0 66 670 8802 (13·2%) 521 (0·8%)
>6·0–12·0 13 182 1758 (13·3%) 87 (0·7%)
>12·0–18·0 17 075 2326 (13·6%) 105 (0·6%)
HIV status
Negative 92 024 12 293 (13·4%) 693 (0·8%)
Positive 5080 672 (13·2%) 23 (0·5%)
Table 3: Prevalence of sickle cell trait and disease by age and HIV status
See Online for appendix
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which is higher than predicted when based on the 
prevalence of sickle cell trait. This ﬁ nding might reﬂ ect 
assortative (non-random) mating, where individuals have 
a preference for speciﬁ c genotypes and phenotypes. 
Additional haemoglobin variants with prevalence of 1⋅0% 
or higher in the Mid Northern and West Nile regions was 
unexpected, but we await molecular diagnoses to conﬁ rm 
their identities and relevance.
The association between sickle cell trait and malaria 
was suggested many years ago, and was based on the 
epidemiological overlap of the two disorders in central 
Africa.17,18 Piel and colleagues19 conﬁ rmed this association 
at the global level, but our results conﬁ rm this association 
at the regional level (ﬁ gure 2). The overlap in Uganda 
suggests continuing diﬀ erential selection pressure for 
children with sickle cell trait to survive malaria,20 which is 
supported by ﬁ ndings in Gabon,21 and probably also 
reﬂ ects low migration of tribal populations within 
regions. Since malaria is frequently fatal in children with 
sickle cell disease,22 improved understanding of 
prevalence and distribution of sickle cell trait and disease 
might be relevant to national malaria control strategies.
Sickle cell disease is frequently associated with early 
mortality for infants and young children in sub-Saharan 
Africa,2,4,6–8 including in two reports by WHO on the African 
Region,9,10 but no deﬁ nitive data are available due to 
inadequate studies. Our data, although not longitudinal, 
support this association. Age and HIV status also seemed 
to be associated with early mortality in children with sickle 
cell disease, as we took reduced prevalence of sickle cell 
disease in children older than 12 months and those who 
were HIV positive to indicate early mortality. The low odds 
ratio indicates an important potential comorbidity between 
HIV and sickle cell disease that should be investigated 
prospectively. Further assessment is especially important, 
as the combination is poorly understood, with potential 
protective eﬀ ects and synergism for disease complications 
both having been described.23
This study had several strengths, including the large 
sample size in the Early Infant Diagnosis programme, 
which provided national coverage, high-quality laboratory 
testing, and the ability to create an accurate geospatial 
map at the regional and district levels. The study design 
was eﬃ  cient, as repurposing of DBS kept eﬀ ort, costs, 
and time low. Other countries within sub-Saharan Africa 
that have comprehensive early infant diagnosis 
programmes could obtain similar accurate sickle cell 
prevalence data with this strategy. Finally, the study 
established a strong infrastructure, with laboratory staﬀ  
being trained to assess sickle cell trait and disease, which 
met the important goal of building local laboratory and 
research capacity. This study reﬂ ects a highly successful 
partnership between government and academia in 
Uganda and the USA, which generated data that will 
inform policy.
The study also had several limitations. All DBS were 
collected from children exposed to HIV. However, no 
evidence suggests any systematic bias between HIV 
exposure and the inheritance of sickle cell trait or 
disease. Indeed, prevalence was around 13% in 
HIV-positive (representing 5% of the total Early Infant 
Diagnosis cohort) and HIV-negative infants. Second, 
the cross-sectional study design did not allow collection 
of longitudinal data, but the Central Public Health 
Laboratories plan to track these aﬀ ected infants over 
time. Finally, optimum clinical care could not be 
assured for all children identiﬁ ed as having sickle cell 
disease because there are no national treatment 
guidelines and knowledge of the disease among health-
care providers is poor. The Ugandan Ministry of Health, 
however, is to issue national standards of care to 
promote appropriate clinical management in all regions 
and districts.
The WHO strategy for sickle cell disease in the 
African Region is bold and comprehensive. The guiding 
principles include country ownership of the strategy, 
partnership and team building, evidence-based 
interventions, and cultural sensitivity.10 The Ugandan 
Ministry of Health commissioned the US3 study in 
response to the WHO guidelines, speciﬁ cally to 
document the burden of sickle cell disease and to 
decide how and where to prioritise its limited resources. 
Pilot neonatal haemoglobinopathy screening eﬀ orts in 
sub-Saharan Africa have successfully identiﬁ ed a large 
burden of sickle cell disease,15,24–26 and are typically 
coupled with immunisations to prevent fatal bacterial 
infections.27 Additionally, hydroxyurea has been 
identiﬁ ed as a potentially transformative disease-
modifying therapy for use in low-resource settings.28 
Accordingly, the proposed next steps for Uganda 
include targeted neonatal screening in the districts with 
the highest burden; training of health-care providers 
and establishment of regional and district sickle cell 
clinics to provide penicillin and antimalarial 
prophylaxis, family education, and immunisations; 
research of the safety, dosing, and beneﬁ ts of 
hydroxyurea; and creation of a national sickle cell 
awareness strategy that will include premarital testing 
and counselling aimed at lowering the burden of sickle 
cell disease.
The UN Sustainable Development Goals emphasise 
non-communicable diseases as public health concerns, 
and sickle cell disease deserves recognition as a 
widespread disorder that can lead to serious morbidity, 
poor quality of life, and early mortality. Despite a plea 
from key thought leaders to document the natural 
history of this disease and the associated mortality in 
Uganda,29 sickle cell disease remains neglected with few 
reliable data and little political will to improve the 
situation.30 The US3 study provides important data that 
will help to rectify these deﬁ cits, and supports eﬀ orts by 
government and academia to improve the lives of 
children and adults with sickle cell disease who are 
living in Uganda.
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